BMYBristol Myers Squibb

$59.11+34% 1Y

$59.11

$41.6752 weeks$68.08

BMY in its own filings

BMY's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.

693

Events found in the filings · across 3,535 filings · the record starts in 1994

Hard flags: 1
Hard flags
Most recent filing: Jul 30, 2026
Most recent filing · Form 10-Q
Record starts: Mar 15, 1994
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Oct 29, 2026
Change in certifying accountant10 occurrences: 2006-05-11
Late periodic reporthistorical: 2002-11-15
Security removed from listing or deregistered5 occurrences · usually a matured note or preferred class, not the common shares: 2025-05-15
Material impairmenthistorical: 2012-08-24
SEC comment-letter activity89 occurrences: 2024-02-16

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Jul 30, 2026Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full-Year Outlook.Earnings release · press release
Apr 30, 2026Bristol Myers Squibb Reports First Quarter Financial Results for 2026.Earnings release · press release
Feb 5, 2026Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025.Earnings release · press release
Jan 12, 20261 Bristol Myers Squibb: Built for Growth 44th Annual J.P. Morgan Healthcare.Regulation FD disclosure · press release
Nov 18, 2025On November 17, 2025, Bristol-Myers Squibb Company (“Bristol Myers Squibb”) issued a press release announcing the early participation results, amendment and early settlement of its previously announced cash tender offers (the “Offers”) to purchase notes issued by Bristol Myers Squibb.Other event · Form 8-K
Nov 10, 2025Indenture On November 10, 2025, BMS Ireland Capital Funding Designated Activity Company (the “Issuer”), a designated activity company incorporated under the laws of Ireland and a wholly-owned subsidiary of Bristol-Myers Squibb Company (the “Company”), completed the public offering (the “Offering”) of (i) €750,000,000 …Other event · Form 8-K
Nov 3, 2025On November 3, 2025, Bristol-Myers Squibb Company (“Bristol Myers Squibb” or the “Company”) issued a press release announcing the commencement of cash tender offers (the “Offers”) to purchase certain of its outstanding notes for an aggregate purchase price of up to $7 billion, subject to the Pool 1 Maximum and Pool 2 …Other event · Form 8-K
Oct 30, 2025Bristol Myers Squibb Reports Third Quarter Financial Results for 2025.Earnings release · press release